Cognizant plans to employ its Neuro AI generative AI platform to assist Gilead in enhancing IT and business processes, with the intent to create value and transform the user experience of IT services.
TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ ...
Cognizant recently announced its collaboration with Gilead Sciences to expand their partnership. They will leverage machine learning, generative AI, and advanced technology solutions to enhance ...
Gilead's outlook into 2025 is promising, with multiple late-stage clinical programs pending data readouts. In January, the company expanded its partnership with Cognizant to develop custom ...
Morgan Stanley raised the firm’s price target on Cognizant (CTSH) to $80 from $75 and keeps an Equal Weight rating on the shares while upgrading the firm’s U.S. IT Services industry view to In ...
Gilead Sciences, Inc. (NASDAQ:GILD) develops and markets medicines for HIV, COVID-19, hepatitis, cancer, and other serious conditions. On January 30, Gilead Sciences ...
TEANECK, N.J. - Cognizant Technology Solutions (NASDAQ:CTSH) Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: ...